Bengtsen · PLoS genetics 2021 · comparative laboratory and animal study · n=?

Comparing the epigenetic landscape in myonuclei purified with a PCM1 antibody from a fast/glycolytic and a slow/oxidative muscle.

Cited 27 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Bench and animal basic research establishing a nuclear isolation technique and comparative ChIP-seq analysis.

PubMed 34752468 · doi:10.1371/journal.pgen.1009907 · record verified 2026-08-30

What was done

Researchers developed a magnetic-assisted sorting method using an antibody against Pericentriolar material 1 (PCM1), a nuclear envelope marker specific to skeletal muscle nuclei, to isolate pure myonuclei from heterogeneous muscle tissue in mice, rats, and humans. They then performed chromatin immunoprecipitation sequencing (ChIP-seq) on purified myonuclei to map and compare the genome-wide epigenetic landscape and transcription factor motif enrichment between fast/glycolytic extensor digitorum longus (EDL) and slow/oxidative soleus muscles.

What was found

PCM1-based sorting isolated myonuclei with 95% purity across mouse, rat, and human muscle samples, effectively removing contamination from non-myocyte nuclei (which can comprise up to 60% of whole tissue). Comparative ChIP-seq identified distinct distal enhancer profiles, including a glycolytic super-enhancer in the EDL. Soleus myonuclei were enriched for MEF2C, NFATC2, and PPARA transcription factor binding sites, whereas EDL myonuclei showed overrepresentation of MYOD1 and SIX1 sites. Novel candidate regulators, including MAF family members, ZFX, and ZBTB14, were also identified. Specific quantitative enrichment statistics and effect sizes were not reported in the abstract.

Why it matters

Cellular heterogeneity in skeletal muscle often dilutes muscle-specific epigenetic signals. This purification technique provides a standardized tool to study true myonuclear chromatin biology and confirms distinct transcriptional regulatory architectures governing fast versus slow muscle types.

Limits

The abstract does not state the sample sizes (number of animals or human tissue donors) used for sorting validation or ChIP-seq. Quantitative ChIP-seq metrics, statistical thresholds, and functional knock-down or validation experiments for the newly identified transcription factors are not reported in the abstract.

Cited by